Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-14T20:04:05.527Z Has data issue: false hasContentIssue false

The high prevalence of undiagnosed metabolic complications in people with severe mental illness

Published online by Cambridge University Press:  16 April 2020

R.I.G. Holt
Affiliation:
Endocrinology and Metabolism Unit, University of Southampton, Southampton, United Kingdom
R.C. Peveler
Affiliation:
Community Clinical Sciences Division, University of Southampton, Southampton, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The prevalence of metabolic syndrome is increased 2-3 fold in people with severe mental illness (SMI) yet monitoring of physical health in the individuals is poor, despite clear guidance from NICE.

Aim:

To assess whether monitoring of metabolic complication of people with SMI had occurred within the last year. To assess the prevalence of undiagnosed metabolic syndrome in SMI

Methods:

100 patients with SMI involving both community and in-patient settings were audited. The prevalence of metabolic syndrome was assessed in 50 previously unmonitored patients.

Results:

In the audit, the 100 psychiatric notes had details of the following assessments: blood pressure (n=32), glucose (n=16), lipids (n=9) and weight (n=2). Twenty-six of 50 (52%) patients were subsequently found to fulfil the IDF definition for metabolic syndrome. Three had previously undiagnosed diabetes based on fasting glucose concentration. Metabolic syndrome was associated with increasing age (p=0.03) but not clinical setting, diagnosis, antipsychotic medication, gender, smoking status, alcohol or illicit drug use. 22% of patients had a family history of diabetes.

Conclusion:

There is a high prevalence of undiagnosed metabolic syndrome in people with SMI. Improved screening of metabolic complications should lead to better identification and treatment of this clinical problem.

Type
Poster Session 1: Schizophrenia and Other Psychosis
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.